- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05515562
Effects of Intravenous (IV) Omadacycline on Gut Microbiome
April 23, 2024 updated by: Wake Forest University Health Sciences
Effects of IV Omadacycline on Gut Microbiome
Given the clinical need to improve upon current antibiotic regimens for the treatment of C. difficile infection with a particular focus on the impact of therapies on gut microbiome, this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut microbiome of healthy volunteers.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The plan to enroll eight healthy volunteers between the ages of 18 and 40 years and without history of cardiovascular, gastrointestinal, hepatic, or renal disease to receive 5 days of intravenous omadacycline followed by 5 days of oral omadacycline.
Stool and saliva samples will be collected at pre-specified times and analyzed to characterize the impact of IV omadacycline on gut microbiome.
Study Type
Interventional
Enrollment (Estimated)
8
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yolanda Belin
- Phone Number: 336-716-3720
- Email: ybelin@wakehealth.edu
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Baptist Health
-
Contact:
- John C Williamson, PharmD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18-40 years of age
- Willing and able to comply with all study procedures
- Considered healthy without history of cardiovascular, gastrointestinal, hepatic, or renal disease
- males or females - females of child bearing potential must agree to use a highly effective contraception during the study and for at least 7 days after the last dose of omadacycline
Exclusion Criteria:
- Consumed probiotics within 30 days before enrollment
- Consumed antibiotics within 90 days prior to enrollment
- Known hypersensitivity to omadacycline or tetracycline-class antibiotics
- pregnant or breastfeeding
- in the opinion of the investigator is experiencing signs or symptoms of acute illness that increase the risk of adverse effects from participating in the study
- previously participated in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous (IV) Omadacycline
All participants will receive 5 days of IV omadacycline followed by 5 days of oral omadacycline
|
All participants will receive Intravenous (IV) omadacycline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gut microbiota concentrations
Time Frame: Day 31
|
In general, the healthy volunteer analyses will assess changes in total and species-specific microbiota over time as well as changes in microbial diversity.
|
Day 31
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: John C Williamson, Wake Forest University Health Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2023
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
August 23, 2022
First Submitted That Met QC Criteria
August 23, 2022
First Posted (Actual)
August 25, 2022
Study Record Updates
Last Update Posted (Actual)
April 25, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00081259
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD that underlie the results reported in this article, after deidentification
IPD Sharing Time Frame
Beginning 6 months following article publication and ending 36 months following article publication
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbial Colonization
-
Karolinska InstitutetCompletedMicrobial Colonization and Colorectal Disease
-
NHS FifeUniversity of TurkuUnknownDental Caries | Oral Microbial ColonizationUnited Kingdom
-
University Magna GraeciaRecruiting
-
BLIS Technologies LimitedRecruiting
-
Min-Tze LIONGInternational Islamic University MalaysiaRecruiting
-
VU University of AmsterdamWageningen University and Research; Maag Lever Darm Stichting; Cidrani; WholeFiber and other collaboratorsActive, not recruiting
-
BLIS Technologies LimitedActive, not recruiting
-
Becton, Dickinson and CompanyCompleted
-
Washington University School of MedicineCompletedMicrobial ColonizationUnited States
-
Cairo UniversityUnknown
Clinical Trials on Omadacycline Injection
-
Paratek Pharmaceuticals IncRecruitingBacterial InfectionsUnited States
-
Paul BeringerParatek Pharmaceuticals IncCompleted
-
Paratek Pharmaceuticals IncCompletedCommunity-acquired PneumoniaUnited States
-
Methodist Health SystemRecruitingDiabetic Foot InfectionUnited States
-
Paratek Pharmaceuticals IncActive, not recruitingMycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary InfectionUnited States
-
Hartford HospitalParatek Pharmaceuticals IncCompletedDiabetes | Healthy Volunteers | Wound InfectionUnited States
-
Lundquist Institute for Biomedical Innovation at...Paratek Pharmaceuticals Inc; Chapman UniversityRecruitingBone Infection | Joint Infection | Bone and Joint InfectionUnited States
-
Paratek Pharmaceuticals IncCompletedCystitis | Uncomplicated Urinary Tract InfectionUnited States
-
Paratek Pharmaceuticals IncCompletedBacterial Infections | Skin Structures and Soft Tissue InfectionsUnited States
-
Paratek Pharmaceuticals IncCompletedBacterial Infections | Skin Structures and Soft Tissue InfectionsCroatia, Greece, Israel, Peru, South Africa, Turkey, United States, Bulgaria, Hungary, Latvia, Poland, Romania, Spain, Ukraine